Phthalate metabolites in urine of CF patients are associated with use of enteric-coated pancreatic enzymes

Keller, BO; Davidson, AG; Innis, SM

HERO ID

1315331

Reference Type

Journal Article

Year

2009

Language

English

PMID

21783974

HERO ID 1315331
In Press No
Year 2009
Title Phthalate metabolites in urine of CF patients are associated with use of enteric-coated pancreatic enzymes
Authors Keller, BO; Davidson, AG; Innis, SM
Journal Environmental Toxicology and Pharmacology
Volume 27
Issue 3
Page Numbers 424-427
Abstract In metabolomic studies using liquid chromatography mass spectrometry of urine from children with cystic fibrosis (CF), high levels of metabolites of low molecular weight phthalates were found. Phthalate metabolite excretion was explained by therapy with enteric-coated pancreatic enzyme replacements. Phthalate metabolite identity was confirmed by tandem mass spectrometry. Pancreatic insufficient CF children taking Cotazym ECS(®), which is formulated with diethyl phthalate (DEP), had urinary metabolites of DEP. Children taking Creon(®), which has dibutyl phthalate (DBP), excreted DBP metabolites. The estimated concentrations of free MEP were 2-3 orders of magnitude higher than reported from environmental phthalate exposure. Enteric-coated pancreatic enzymes can expose individuals with CF to incessant, high oral intakes of phthalates. Although adverse effects have neither been shown to be present nor absent, we raise the need to consider that individuals requiring life-long therapy with some current pancreatic enzyme replacements chronically ingest high amounts of phthalates.
Doi 10.1016/j.etap.2008.12.005
Pmid 21783974
Wosid WOS:000265479000017
Url http://www.sciencedirect.com/science/article/pii/S1382668909000027
Is Certified Translation No
Dupe Override No
Comments Source: Web of Science WOS:000265479000017
Is Public Yes
Language Text English
Keyword Cystic fibrosis; Enteric coating; Pancreatic enzymes; Phthalates
Relationship(s)